InspireMD Inc. (NSPR)
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR
NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.
InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript
After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR)
InspireMD (NSPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
InspireMD, Inc. (NSPR) Q4 2025 Earnings Call Transcript
InspireMD, Inc. (NSPR) Q4 2025 Earnings Call Transcript
InspireMD, Inc. (NSPR) Reports Q4 Loss, Beats Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.19 per share a year ago.
InspireMD, Inc. (NSPR) Q3 2025 Earnings Call Transcript
InspireMD, Inc. ( NSPR ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Marvin Slosman - President, CEO & Director Michael Lawless - Chief Financial Officer Shane Gleason - Chief Commercial Officer Conference Call Participants Webb Campbell Adam Maeder - Piper Sandler & Co., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good morning, and welcome to InspireMD Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.
InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript
InspireMD, Inc. (NASDAQ:NSPR ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Marvin L. Slosman - President, CEO & Director Michael A.
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.
InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript
InspireMD, Inc. (NASDAQ:NSPR ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Webb Campbell – Gilmartin Group LLC Marvin Slosman – Chief Executive Officer Craig Shore – Chief Financial Officer Shane Gleason – Chief Commercial Officer Conference Call Participants Adam Maeder – Piper Sandler Frank Takkinen – Lake Street Capital Operator Good morning, and welcome to InspireMD's First Quarter 2025 Earnings Conference call. [Operator Instructions] We will facilitating a question-and-answer session towards the end of today's call.
